Acumen Pharmaceuticals Exercises Option to Develop Alzheimer’s Therapeutics Using JCR’s J‑Brain Cargo Platform

JCR Pharmaceuticals announced that Acumen Pharmaceuticals has exercised its exclusive option. The option allows Acumen to develop therapeutic candidates for Alzheimer’s disease. Development will be enabled by JCR’s J‑Brain Cargo® technology platform. The announcement was released via Business Wire. The collaboration focuses on advancing Alzheimer’s treatments. Acumen’s move signals confidence in the platform’s capabilities. JCR expects the partnership to accelerate drug development timelines. Industry observers will track progress of the therapeutic candidates.